LY-3000328

Research use only, not for human use.

LY-3000328 is a potent, highly selective cathepsin S inhibitor with IC50 of 7.7 nM.

LY-3000328 is a potent, highly selective cathepsin S inhibitor with IC50 of 7.7 nM; dispalys >500-fold selectivity over cathepsin L, cathepsint K, cathepsin B, and cathepsin V; shows efficacy in a CaCl2-induced AAA (Abdominal Aortic Aneurysm) in vivo model.Other Indication Phase 1 Clinical.

LY 3000328 maintains excellent in vitro potency and selectivity. LY 3000328 shows low in vitro CYP450 inhibition (<15% at 10 μM for CYP3A4, CYP2D6, and CYP2C9); low in vitro metabolism in mouse, rat, dog, and human liver microsomes (<20% after 30 min incubation at 4 μM); and good permeability (MDCK A-B>4%). At a 100 μM concentration of LY 3000328 there is only 6% displacement of [3H]-astemizole in an assay with HEK293 membrane preparation, indicating low potential of hERG blockade. LY 3000328 is a potent and specific inhibitor of cathepsin S (CatS). Inhibition of CatS activity in plasma would be 50% of maximal when LY 3000328 plasma concentration is approximately 60 ng/mL.

The efficacies of LY 3000328 is studied in a mouse model of abdominal aortic aneurysm (AAA). In this model, inflammation is induced using CaCl2 applied to the ablumenal surface. It is shown that features of the disease state in this model resemble those of human AAA. LY 3000328 exhibits a dose-responsive aortic diameter reduction at 1, 3, 10, and 30 mg/kg. At the lowest dose of 1 mg/kg of LY 3000328, the aortic diameter is reduced by 58%, then 83% at 3 mg/kg, and 87% at 10 mg/kg. The exposure (AUC) for both compounds increased in a dose-dependent manner, suggesting that the drug disposition properties of LY 3000328 are favorable.

LY3000328

Metabolic Enzyme/Protease

Cathepsin

Cathepsin

Other Indications

Other Disease

1373215-15-6

484.528

C25H29FN4O5

>98% (HPLC)

DMSO : ≥ 50 mg/mL 103.19 mM

O=C(O[C@H]1COC2=C(C=C(N3CCN(C4COC4)CC3)C=C2)[C@@H]1NC(C5=CC=C(F)C=C5)=O)NC

(3R,4S)-4-(4-fluorobenzamido)-6-(4-(oxetan-3-yl)piperazin-1-yl)chroman-3-yl methylcarbamate

(-20℃)

With Ice Pack

≥ 2 years